Microdose Study of 14C‐Acetaminophen With Accelerator Mass Spectrometry to Examine Pharmacokinetics of Parent Drug and Metabolites in Healthy Subjects

A study of the pharmacokinetics of 14C‐labeled acetaminophen (AAP) was performed in healthy Japanese subjects receiving an oral microdose of the drug. After separation by high‐performance liquid chromatography (HPLC), the levels of AAP and its metabolites in the pooled plasma specimens were quantified using accelerator mass spectrometry (AMS). The total body clearance (CLtot)/bioavailability (F) of AAP was within the variation in the reported values at therapeutic doses, indicating the linearity of AAP pharmacokinetics. AAP‐glucuronide (Glu) and AAP‐4‐O‐sulfate satisfied the criteria of safety testing of drug metabolites. AMS could detect AAP‐Cys, the active metabolite of AAP conjugated with cysteine, in the urine. Probenecid prolonged the systemic elimination of total radioactivity and caused a marked decrease in AAP‐Glu levels in plasma. Probenecid likely inhibited the glucuronidation of AAP and the renal elimination of AAP‐4‐O‐sulfate. Microdosing of 14C‐labeled drug followed by AMS is a powerful tool that can be used in the early phase of drug development for pharmacokinetic analysis of drugs and their metabolites and for detecting the formation of active metabolites in humans.

[1]  Laura P James,et al.  Acetaminophen-induced hepatotoxicity. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[2]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[3]  F. Kamali.  The effect of probenecid on paracetamol metabolism and pharmacokinetics , 2004, European Journal of Clinical Pharmacology.

[4]  E. Matsumoto,et al.  A Batch Preparation Method for Graphite Targets With Low Background for AMS 14C Measurements , 1993, Radiocarbon.

[5]  Yuichi Sugiyama,et al.  Drug-Drug Interactions Involving the Membrane Transport Process , 2001 .

[6]  R. Weinshilboum,et al.  Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. , 2008, Birth defects research. Part A, Clinical and molecular teratology.

[7]  H. Kusuhara,et al.  Species Difference in the Inhibitory Effect of Nonsteroidal Anti-Inflammatory Drugs on the Uptake of Methotrexate by Human Kidney Slices , 2007, Journal of Pharmacology and Experimental Therapeutics.

[8]  Y Kumagai,et al.  Microdose study of a P‐glycoprotein substrate, fexofenadine, using a non‐radioisotope‐labelled drug and LC/MS/MS , 2010, Journal of clinical pharmacy and therapeutics.

[9]  R C Garner,et al.  Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1- methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[10]  Graham Lappin,et al.  Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. , 2008, Expert opinion on drug metabolism & toxicology.

[11]  Yuichi Sugiyama,et al.  Microdose clinical trial: quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  D. Greenblatt,et al.  Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid , 1993, Biopharmaceutics & drug disposition.

[13]  Yuichi Sugiyama,et al.  A Species Difference in the Transport Activities of H2 Receptor Antagonists by Rat and Human Renal Organic Anion and Cation Transporters , 2005, Journal of Pharmacology and Experimental Therapeutics.

[14]  B. Beermann,et al.  Non-linear elimination and protein binding of probenecid , 2004, European Journal of Clinical Pharmacology.

[15]  L F Prescott,et al.  Kinetics and metabolism of paracetamol and phenacetin. , 1980, British journal of clinical pharmacology.

[16]  R. C. Garner,et al.  A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts. , 2000, Journal of pharmaceutical and biomedical analysis.

[17]  K. Brouwer,et al.  In vitro mechanisms of probenecid-associated alterations in acetaminophen glucuronide hepatic disposition. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[18]  Toshio Nakamura,et al.  A batch preparation method for graphite targets with low background for AMS (super 14) C measurements. , 1993 .

[19]  Malcolm Rowland,et al.  Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs , 2006, Clinical pharmacology and therapeutics.

[20]  Hartmut Jaeschke,et al.  Intracellular signaling mechanisms of acetaminophen-induced liver cell death. , 2006, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  L. Stevens,et al.  Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics , 2008, Expert opinion on drug metabolism & toxicology.

[22]  J. Clements,et al.  Clinical Pharmacokinetics of Paracetamol , 1982, Clinical pharmacokinetics.

[23]  G Levy,et al.  Renal clearance and serum protein binding of acetaminophen and its major conjugates in humans. , 1984, Journal of pharmaceutical sciences.